ClinicalTrials.gg
TerminatedNCT04517864Allegro2aUpdated Jul 11, 2025Results posted

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

A Phase 2 interventional study of PF-06651600 and Placebo in Alopecia Areata, sponsored by Pfizer. Terminated at 38 sites in 4 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Pfizer · Phase 2, Interventional, and Other

Why this study was terminated
For business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Alopecia Areata by Pfizer — 4 open to participants now, 8 under way, 4 of them phase 3. Alopecia Areata · Pfizer.

Enrollment
9th of 10
71 · median 175
Started
2020
with 1 other
Phase 2
3 of 17
none open now
Registered
4th of 17
by date

Among the 17 studies in Alopecia Areata by Pfizer, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 2, and was the 4th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

4 of the 17 studies in Alopecia Areata by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alopecia Areata by Pfizer, or all of them as a file.
02

Study summary

This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).

03

Conditions studied

  • Alopecia Areata

Keywords

  • alopecia totalis
  • alopecia universalis
  • hair loss
  • alopecia
  • JAK
  • ritlecitinib
  • PF-06651600
  • double-blind
  • placebo-controlled
  • phase 2a
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of alopecia areata, including alopecia totalis and alopecia universalis.
  • At least 25% hair loss due to alopecia areata
  • Must have normal hearing and normal brainstem auditory evoked potentials (BAEPs)
  • Must have a normal neurological exam; can have a stable unilateral median neuropathy or ulnar neuropathy
  • Signed
  • Stable regimen for other medications before and during the study

Exclusion criteria

Exclusion Criteria:

  • Other significant medical conditions
  • Occupational or recreational noise exposure
  • History of peripheral neuropathy or first degree relative with a hereditary peripheral neuropathy
  • > or = 7.5% at Screening
  • Recurrent or disseminated Herpes Zoster
  • Active or chronic infection; or infection requiring hospitalization or IV antimicrobials within 6 months
  • Active or latent (insufficiently treated) Hepatitis
  • Active or latent (insufficiently treated) TB
  • Concomitant medications associated with peripheral neurologic or hearing loss
  • Protocol specific laboratory abnormalities
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Treatment Arm: PF-06651600

    ritlecitinib 200 milligram (mg) once per day (QD) (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24. At Month 9, participants assigned to this treatment arm will also receive 3 tablets of placebo for 4 weeks to maintain the blind with the other arm. After month 24, participants switch to 50 mg capsules, 1 QD, up to month 60.

    Drug: PF-06651600

  • Other
    Control Arm (Placebo) followed by active therapy extension

    matching comparator: placebo QD (4 tablets x 4 weeks then 1 tablet x 8 months) then ritlecitinib 200 mg QD (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24. After month 24, participants switch to 50 mg capsules, 1 QD, up to month 60.

    Drug: Placebo

Interventions

  • 50 mg tablet, dosed as 200 mg QD or 50 mg QD 50 mg capsule, dosed as 50 mg QD

    Also known as: ritlecitinib

  • DrugPlacebo

    tablet, dosed as 4 tablets QD or 1 tablet QD

06

What researchers measure

Primary outcomes

  1. Change From Baseline in I-V Interwave Latency on Brainstem Auditory Evoked Potentials (BAEP) at a Stimulus Intensity of 80 Decibels (dB) From the Right Side at Month 9

    BAEP interwave I-V latency (in milliseconds) was the primary endpoint for this study. High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.

    Time frame: Baseline, Month 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)

  2. Change From Baseline in I-V Interwave Latency on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 9

    BAEP interwave I-V latency was the primary endpoint for this study. High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.

    Time frame: Baseline, Month 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)

Secondary outcomes

  1. Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 6

    High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.

    Time frame: Baseline, Month 6 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)

  2. Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 9E and 15E

    High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.

    Time frame: Baseline, Months 9E and 15E (Month 9/15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-controlled Phase.

  3. Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 6

    High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.

    Time frame: Baseline, Month 6 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)

  4. Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 9E and 15E

    High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.

    Time frame: Baseline, Month 9E and 15E (Month 9/15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-controlled Phase.

  5. Change From Baseline in Percentage of Intraepidermal Nerve Fiber (IENF) With Axonal Swelling in Skin Punch Biopsies at Month 9

    The endpoint "axonal dystrophy" referred to the percentage of IENF with axonal swellings. Axonal swellings were evaluated in peripheral skin punch biopsies from the distal part of lower extremities. Axonal swellings were counted by axon. Any IENF with single or multiple swellings was counted as a single event, ie, a single axon with axonal swellings. For each participant, data were reported as the percentage of IENF with any number of swellings. IENF was assessed at Day 1 and Month 9. Participants who had entered the Active Therapy Extension Phase at Month 6 had a skin punch biopsy taken at Month 6 for IENF assessments instead of at Month 9. The skin biopsy was collected before the start of Active Therapy Extension Phase.

    Time frame: Baseline, Month 9 (Month 6 for the 2 participants who entered the Active Therapy Extension Phase at Month 6). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.

  6. Change From Baseline in Percentage of IENFs With Axonal Swelling in Skin Punch Biopsies at Month 15E

    The endpoint "axonal dystrophy" referred to the percentage of IENF with axonal swellings. Axonal swellings were evaluated in peripheral skin punch biopsies from the distal part of lower extremities. Axonal swellings were counted by axon. Any IENF with single or multiple swellings was counted as a single event, ie, a single axon with axonal swellings. For each participant, data were reported as the percentage of IENF with any number of swellings.

    Time frame: Baseline, Month 15E (Month 15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.

  7. Change From Baseline in Intraepidermal Nerve Fiber Density (IENFD) in Skin Punch Biopsies at Month 9

    IENFD was evaluated in peripheral skin punch biopsies from the distal part of lower extremities. IENFD was measured by counting the number of fibers and fiber branches that independently crossed the dermal-epidermal barrier (basement membrane). Secondary branching was excluded from quantification and fragments were not counted. The length of the histology section was measured (mm) and the linear epidermal nerve fiber density was reported as number of intraepidermal nerve fibers/mm.

    Time frame: Baseline, Month 9 (Month 6 for the 2 participants who entered the Active Therapy Extension Phase at Month 6). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.

  8. Change From Baseline in IENFD in Skin Punch Biopsies at Month 15E

    IENFD was evaluated in peripheral skin punch biopsies from the distal part of lower extremities. IENFD was measured by counting the number of fibers and fiber branches that independently crossed the dermal-epidermal barrier (basement membrane). Secondary branching was excluded from quantification and fragments were not counted. The length of the histology section was measured (mm) and the linear epidermal nerve fiber density was reported as number of intraepidermal nerve fibers/mm.

    Time frame: Baseline, Month 15E (Month 15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.

  9. Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Right Side at Month 6 and Month 9

    High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.

    Time frame: Baseline, Month 6 and Month 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)

  10. Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Right Side at Month 9E and 15E

    High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.

    Time frame: Baseline, Month 9E and 15E (Month 9 and 15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.

  11. Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 6 and Month 9

    High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.

    Time frame: Baseline, Month 6 and Month 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)

  12. Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 9E and 15E

    High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.

    Time frame: Baseline, Month 9E and 15E (Month 9 and 15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.

  13. Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Right Side up to Month 9

    Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized descriptively using number of participants by treatment group at each intensity level. At Month 9, 1 participant in 200/50 mg had absence of Wave V on BAEP at a stimulus intensity of 40 dB on the right side. The event was unilateral and showed fluctuations in the presence or absence of Wave V at various intensities on repeat assessments starting at Month 6.

    Time frame: Baseline, Month 6 and 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase)

  14. Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Right Side at Baseline, Month 3E, 6E, 9E and 15E

    Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized using number of participants by treatment group at each intensity level. All participants had Wave V on BAEP present at stimulus intensities ranging from 80 dB to 40 dB up to Month 15E except for 1 participant. At Month 9 (TP1), 1 participant in 200/50/50 mg had absence of Wave V on BAEP at a stimulus intensity of 40 dB on the right side. Fluctuations were seen in the presence or absence of Wave V at various intensities on repeat assessments starting at Month 6 on the right side.

    Time frame: Baseline, Month 3E, 6E, 9E and 15E (Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase)

  15. Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Left Side up to Month 9

    Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized descriptively using number of participants by treatment group at each intensity level.

    Time frame: Baseline, Month 6 and 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase)

  16. Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Left Side at Baseline, Month 3E, 6E, 9E and 15E

    Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized descriptively using number of participants by treatment group at each intensity level. All participants had Wave V on BAEP present at stimulus intensities ranging from 80 dB to 40 dB up to Month 15E except for 1 participant. At Month 9 (TP1), 1 participant in 200/50/50 mg had absence of Wave V on BAEP at a stimulus intensity of 40 dB on the right side. Fluctuations were seen in the presence or absence of Wave V at various intensities on repeat assessments starting at Month 6 on the right side.

    Time frame: Baseline, Month 3E, 6E, 9E and 15E (Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase)

  17. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Seriousness of an AE was assessed under the criteria of serious adverse event (SAE). An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect, etc. Treatment-emergent events were with onset date occurring during the on-treatment period. Relatedness to study treatment was determined by the investigator.

    Time frame: Approximately 16 months

  18. Number of Participants Who Discontinued From Study Due to Adverse Event (AEs)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study. Relatedness to study treatment was determined by the investigator.

    Time frame: Approximately 16 months

  19. Number of Participants Who Discontinued Study Drug Due to AE and Continued Study

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. This Outcome Measures presented the number of participants who had an AE record that indicated that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study. Relatedness to study treatment was determined by the investigator.

    Time frame: Approximately 16 months

  20. Number of Participants With Temporary Drug Discontinuation Due to AEs

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with temporary drug discontinuation due to both all-causality and treatment-related AEs are presented below. Relatedness to study treatment was determined by the investigator.

    Time frame: Approximately 16 months

  21. Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Oral, tympanic, or axillary temperature, pulse rate, respiratory rate, and blood pressure (BP) were assessed. BP and pulse measurements were assessed in a chair, back supported and arms bared (free of restrictions such as rolled-up sleeves, etc) and supported at heart level. Measurements were taken on the same arm at each visit (preferably non-dominant) with a completely automated device. Pulse rate was measured at approximately the same time as BP for a minimum of 30 seconds. BP and pulse measurements should be preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (eg, television, cell phones). Participants refrained from smoking or ingesting caffeine during the 30 minutes preceding the measurements. The clinical significance was determined by the investigator.

    Time frame: Approximately 16 months

  22. Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values

    Safety laboratory assessments included the categories of Hematology, Chemistry, Urinalysis and other tests. The clinical significance was determined by the investigator.

    Time frame: Approximately 16 months

  23. Change From Baseline in Overall Severity of Alopecia Tool (SALT) Scores up to Month 9

    SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. The overall SALT score included hair loss regardless of etiology (ie, scalp hair loss due to both non-AA and AA) and was collected at study visits. The Overall SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.

    Time frame: Baseline, Months 3, 6 and 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)

  24. Change From Baseline in Overall SALT Scores at Month 3E, 6E, 9E, 12E and 15E

    SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. The overall SALT score included hair loss regardless of etiology (ie, scalp hair loss due to both non-AA and AA) and was collected at study visits. The Overall SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.

    Time frame: Baseline, Month 3E, 6E, 9E, 12E and 15E (Month 3, 6, 9, 12 and 15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase.

  25. Change From Baseline in Alopecia Areata - Severity of Alopecia Tool (AA-SALT) Score up to Month 9

    SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. AA-SALT is the amount of scalp hair loss due to AA. AA SALT score in Placebo-Controlled Phase = overall SALT score - non-AA SALT score (The non-AA SALT score only took into account scalp hair loss other than that due to AA and was required to be assessed only at Month 9 \[or Month 6 for those who entered the Active Therapy Extension Phase at Month 6\] in Placebo-Controlled Phase). The AA-SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.

    Time frame: Baseline, Months 3, 6 and 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)

  26. Change From Baseline in AA-SALT Score at Month 3E, 6E, 9E, 12E and 15E

    SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. AA-SALT is the amount of scalp hair loss due to AA. AA SALT score = overall SALT score - non-AA SALT score (The non-AA SALT score only took into account scalp hair loss other than that due to AA and was required to be assessed only at Month 9 \[or Month 6 for those who entered the Active Therapy Extension Phase at Month 6\] in Placebo-Controlled Phase). The AA-SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.

    Time frame: Baseline, Month 3E, 6E, 9E, 12E and 15E (Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase)

  27. Number of Participants With Patient's Global Impression of Change (PGI-C) Response up to Month 9

    The PGI-C asked the participants to evaluate the improvement or worsening of their AA as compared to the start of the study using a single item, "Since the start of the study, my alopecia areata has: …". The participants selected one of seven responses ranging from "greatly improved" to "greatly worsened". This Outcome Measure presented the number of participants with PGI-C response which was defined as "greatly improved" or "moderately improved". Participants with missing PGI-C scores were considered as non-responders.

    Time frame: Months 1, 3, 6 and 9

  28. Number of Participants With PGI-C Response at 3E, 6E, 9E, 12E and 15E

    The PGI-C asked the participants to evaluate the improvement or worsening of their AA as compared to the start of the study using a single item, "Since the start of the study, my alopecia areata has: …". The participants selected one of seven responses ranging from "greatly improved" to "greatly worsened". This Outcome Measure presented the number of participants with PGI-C response which was defined as "greatly improved" or "moderately improved". Participants with missing PGI-C scores were considered as non-responders.

    Time frame: Month 3E, 6E, 9E, 12E and 15E

  29. Number of Participants With TEAEs and TESAEs: Extension Phase (TP3)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Seriousness of an AE was assessed under the criteria of SAE. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect, etc. Treatment-emergent events were with onset date occurring during the on-treatment period. Relatedness to study treatment was determined by the investigator.

    Time frame: From first dose of treatment up to 28 days follow up after last dose of study treatment (Approximately 19 months)

  30. Number of Participants Who Discontinued From Study Due to AEs: Extension Phase (TP3)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study. Relatedness to study treatment was determined by the investigator.

    Time frame: From first dose of treatment up to 28 days follow up after last dose of study treatment (Approximately 19 months)

  31. Number of Participants Who Discontinued Study Drug Due to AE and Continued Study: Extension Phase (TP3)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. This outcome measure presented the number of participants who had an AE record that indicated that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study. Relatedness to study treatment was determined by the investigator.

    Time frame: From first dose of treatment up to 28 days follow up after last dose of study treatment (Approximately 19 months)

  32. Number of Participants With Temporary Drug Discontinuation Due to AEs: Extension Phase (TP3)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with temporary drug discontinuation due to both all-causality and treatment-related AEs are presented below. Relatedness to study treatment was determined by the investigator.

    Time frame: From first dose of treatment up to 28 days follow up after last dose of study treatment (Approximately 19 months)

  33. Number of Participants With Clinically Significant Abnormalities in Vital Signs: Extension Phase (TP3)

    Oral, tympanic, or axillary temperature, pulse rate, respiratory rate, and blood pressure (BP) were assessed. BP and pulse measurements were assessed in a chair, back supported and arms bared (free of restrictions such as rolled-up sleeves, etc) and supported at heart level. Measurements were taken on the same arm at each visit (preferably non-dominant) with a completely automated device. Pulse rate was measured at approximately the same time as BP for a minimum of 30 seconds. BP and pulse measurements preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (eg, television, cell phones). Participants were refrained from smoking or ingesting caffeine during the 30 minutes preceding the measurements. The clinical significance was determined by the investigator.

    Time frame: From screening up to 28 days follow up after last dose of study treatment (maximum up to 19 months)

  34. Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values: Extension Phase (TP3)

    Safety laboratory assessments included the categories of hematology, chemistry, urinalysis and other tests. The clinical significance was determined by the investigator.

    Time frame: From screening up to 28 days after last dose of study treatment (maximum up to 19 months)

07

Results

Posted Dec 28, 2022

Participant flow

Placebo-Controlled Phase
Participant flow — Placebo-Controlled Phase
MilestoneRitlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QDRitlecitinib 50 mg QD
Started36350
Completed32330
Not completed420
Withdrew: Adverse event100
Withdrew: Lost to follow-up110
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject110
Active Therapy Extension Phase
Participant flow — Active Therapy Extension Phase
MilestoneRitlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QDRitlecitinib 50 mg QD
Started32330
Completed21240
Not completed1190
Withdrew: Adverse event100
Withdrew: Lack of efficacy100
Withdrew: Lost to follow-up010
Withdrew: Physician decision100
Withdrew: Withdrawal by subject880
Extension Phase
Participant flow — Extension Phase
MilestoneRitlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QDRitlecitinib 50 mg QD
Started0045
Completed000
Not completed0045
Withdrew: Adverse event001
Withdrew: Lack of efficacy002
Withdrew: Study terminated by sponsor0032
Withdrew: Withdrawal by subject003
Withdrew: Approved drug available for indication007

Outcome measures

PrimaryChange From Baseline in I-V Interwave Latency on Brainstem Auditory Evoked Potentials (BAEP) at a Stimulus Intensity of 80 Decibels (dB) From the Right Side at Month 9

BAEP interwave I-V latency (in milliseconds) was the primary endpoint for this study. High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.

Time frame:
Baseline, Month 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Reported as:
Least squares mean · Millisecond (ms)
Change From Baseline in I-V Interwave Latency on Brainstem Auditory Evoked Potentials (BAEP) at a Stimulus Intensity of 80 Decibels (dB) From the Right Side at Month 9
Millisecond (ms)Ritlecitinib 200/50 mg QDPlacebo
Change From Baseline in I-V Interwave Latency on Brainstem Auditory Evoked Potentials (BAEP) at a Stimulus Intensity of 80 Decibels (dB) From the Right Side at Month 90.011 (-0.043 to 0.065)-0.010 (-0.063 to 0.043)
Statistical analysis
  • Ritlecitinib 200/50 mg QD vs Placebo · Mixed Models Analysis · Least squares mean difference: 0.021 · 95% CI -0.056 to 0.097Linear Mixed-effects Model: baseline, treatment group, visit and treatment group by visit interaction as fixed effects; participant as a random effect
PrimaryChange From Baseline in I-V Interwave Latency on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 9

BAEP interwave I-V latency was the primary endpoint for this study. High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.

Time frame:
Baseline, Month 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Reported as:
Least squares mean · ms
Change From Baseline in I-V Interwave Latency on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 9
msRitlecitinib 200/50 mg QDPlacebo
Change From Baseline in I-V Interwave Latency on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 90.031 (-0.012 to 0.075)0.022 (-0.020 to 0.065)
Statistical analysis
  • Ritlecitinib 200/50 mg QD vs Placebo · Mixed Models Analysis · Least squares mean difference: 0.009 · 95% CI -0.052 to 0.070Linear mixed-effects model: baseline, treatment group, visit and treatment group by visit interaction as fixed effects; participant as a random effect
SecondaryChange From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 6

High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.

Time frame:
Baseline, Month 6 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Reported as:
Least squares mean · millisecond (ms)
Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 6
millisecond (ms)Ritlecitinib 200/50 mg QDPlacebo
Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 6-0.030 (-0.072 to 0.011)-0.024 (-0.065 to 0.017)
Statistical analysis
  • Ritlecitinib 200/50 mg QD vs Placebo · Mixed Models Analysis · Least squares mean difference: -0.006 · 95% CI -0.065 to 0.053Linear Mixed-effects Model: baseline, treatment group, visit and treatment group by visit interaction as fixed effects; participant as a random effect
SecondaryChange From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 9E and 15E

High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.

Time frame:
Baseline, Months 9E and 15E (Month 9/15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-controlled Phase.
Reported as:
Mean · millisecond (ms)
Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 9E and 15E
millisecond (ms)Ritlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QD
Month 9E (Month 9 in the Active Therapy Extension Phase)0.010 ± 0.1233-0.033 ± 0.2448
Month 15E (Month 15 in the Active Therapy Extension Phase)0.051 ± 0.11880.034 ± 0.2224
SecondaryChange From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 6

High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.

Time frame:
Baseline, Month 6 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Reported as:
Least squares mean · millisecond (ms)
Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 6
millisecond (ms)Ritlecitinib 200/50 mg QDPlacebo
Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 60.021 (-0.011 to 0.054)-0.020 (-0.053 to 0.012)
Statistical analysis
  • Ritlecitinib 200/50 mg QD vs Placebo · Mixed Models Analysis · Least squares mean difference: 0.042 · 95% CI -0.005 to 0.088Linear mixed-effects model: baseline, treatment group, visit and treatment group by visit interaction as fixed effects; participant as a random effect
SecondaryChange From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 9E and 15E

High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.

Time frame:
Baseline, Month 9E and 15E (Month 9/15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-controlled Phase.
Reported as:
Mean · millisecond (ms)
Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 9E and 15E
millisecond (ms)Ritlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QD
Month 9E (Month 9 in the Active Therapy Extension Phase)0.006 ± 0.11090.056 ± 0.1694
Month 15E (Month 15 in the Active Therapy Extension Phase)0.024 ± 0.10440.017 ± 0.2339
SecondaryChange From Baseline in Percentage of Intraepidermal Nerve Fiber (IENF) With Axonal Swelling in Skin Punch Biopsies at Month 9

The endpoint "axonal dystrophy" referred to the percentage of IENF with axonal swellings. Axonal swellings were evaluated in peripheral skin punch biopsies from the distal part of lower extremities. Axonal swellings were counted by axon. Any IENF with single or multiple swellings was counted as a single event, ie, a single axon with axonal swellings. For each participant, data were reported as the percentage of IENF with any number of swellings. IENF was assessed at Day 1 and Month 9. Participants who had entered the Active Therapy Extension Phase at Month 6 had a skin punch biopsy taken at Month 6 for IENF assessments instead of at Month 9. The skin biopsy was collected before the start of Active Therapy Extension Phase.

Time frame:
Baseline, Month 9 (Month 6 for the 2 participants who entered the Active Therapy Extension Phase at Month 6). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.
Reported as:
Median · Percentage of Nerve Fibers
Change From Baseline in Percentage of Intraepidermal Nerve Fiber (IENF) With Axonal Swelling in Skin Punch Biopsies at Month 9
Percentage of Nerve FibersRitlecitinib 200/50 mg QDPlacebo
Change From Baseline in Percentage of Intraepidermal Nerve Fiber (IENF) With Axonal Swelling in Skin Punch Biopsies at Month 90.0 (-0.5 to 2.5)0.0 (-2.0 to 1.0)
SecondaryChange From Baseline in Percentage of IENFs With Axonal Swelling in Skin Punch Biopsies at Month 15E

The endpoint "axonal dystrophy" referred to the percentage of IENF with axonal swellings. Axonal swellings were evaluated in peripheral skin punch biopsies from the distal part of lower extremities. Axonal swellings were counted by axon. Any IENF with single or multiple swellings was counted as a single event, ie, a single axon with axonal swellings. For each participant, data were reported as the percentage of IENF with any number of swellings.

Time frame:
Baseline, Month 15E (Month 15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.
Reported as:
Median · Percentage of Nerve Fibers
Change From Baseline in Percentage of IENFs With Axonal Swelling in Skin Punch Biopsies at Month 15E
Percentage of Nerve FibersRitlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QD
Change From Baseline in Percentage of IENFs With Axonal Swelling in Skin Punch Biopsies at Month 15E0 (-1.0 to 0)0 (-1.0 to 0)
SecondaryChange From Baseline in Intraepidermal Nerve Fiber Density (IENFD) in Skin Punch Biopsies at Month 9

IENFD was evaluated in peripheral skin punch biopsies from the distal part of lower extremities. IENFD was measured by counting the number of fibers and fiber branches that independently crossed the dermal-epidermal barrier (basement membrane). Secondary branching was excluded from quantification and fragments were not counted. The length of the histology section was measured (mm) and the linear epidermal nerve fiber density was reported as number of intraepidermal nerve fibers/mm.

Time frame:
Baseline, Month 9 (Month 6 for the 2 participants who entered the Active Therapy Extension Phase at Month 6). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.
Reported as:
Mean · fibers/mm
Change From Baseline in Intraepidermal Nerve Fiber Density (IENFD) in Skin Punch Biopsies at Month 9
fibers/mmRitlecitinib 200/50 mg QDPlacebo
Change From Baseline in Intraepidermal Nerve Fiber Density (IENFD) in Skin Punch Biopsies at Month 9-0.4 ± 3.90-0.2 ± 2.72
SecondaryChange From Baseline in IENFD in Skin Punch Biopsies at Month 15E

IENFD was evaluated in peripheral skin punch biopsies from the distal part of lower extremities. IENFD was measured by counting the number of fibers and fiber branches that independently crossed the dermal-epidermal barrier (basement membrane). Secondary branching was excluded from quantification and fragments were not counted. The length of the histology section was measured (mm) and the linear epidermal nerve fiber density was reported as number of intraepidermal nerve fibers/mm.

Time frame:
Baseline, Month 15E (Month 15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.
Reported as:
Mean · fibers/mm
Change From Baseline in IENFD in Skin Punch Biopsies at Month 15E
fibers/mmRitlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QD
Change From Baseline in IENFD in Skin Punch Biopsies at Month 15E0.2 ± 2.85-1.1 ± 3.51
SecondaryChange From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Right Side at Month 6 and Month 9

High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.

Time frame:
Baseline, Month 6 and Month 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Reported as:
Least squares mean · Microvolts (μV)
Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Right Side at Month 6 and Month 9
Microvolts (μV)Ritlecitinib 200/50 mg QDPlacebo
Month 6-0.031 (-0.063 to 0)-0.017 (-0.048 to 0.015)
Month 9-0.051 (-0.085 to -0.018)0.008 (-0.025 to 0.041)
Statistical analysis
  • Ritlecitinib 200/50 mg QD vs Placebo · Mixed Models Analysis · Least squares mean difference: -0.015 · 95% CI -0.059 to 0.030Linear mixed-effects model: baseline, treatment group, visit and treatment group by visit interaction as fixed effects; participant as a random effect
  • Ritlecitinib 200/50 mg QD vs Placebo · Mixed Models Analysis · Least squares mean difference: -0.060 · 95% CI -0.107 to -0.012Linear mixed-effects model: baseline, treatment group, visit and treatment group by visit interaction as fixed effects; participant as a random effect
SecondaryChange From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Right Side at Month 9E and 15E

High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.

Time frame:
Baseline, Month 9E and 15E (Month 9 and 15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.
Reported as:
Mean · μV
Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Right Side at Month 9E and 15E
μVRitlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QD
Month 9E (Month 9 in the Active Therapy Extension Phase)-0.052 ± 0.1109-0.025 ± 0.1649
Month 15E (Month 15 in the Active Therapy Extension Phase)-0.065 ± 0.1513-0.042 ± 0.1214
SecondaryChange From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 6 and Month 9

High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.

Time frame:
Baseline, Month 6 and Month 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Reported as:
Least squares mean · μV
Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 6 and Month 9
μVRitlecitinib 200/50 mg QDPlacebo
Month 6-0.047 (-0.082 to -0.013)-0.019 (-0.053 to 0.015)
Month 9-0.045 (-0.082 to -0.008)-0.049 (-0.085 to -0.012)
Statistical analysis
  • Ritlecitinib 200/50 mg QD vs Placebo · Mixed Models Analysis · Least squares mean difference: -0.028 · 95% CI -0.076 to 0.020Linear mixed-effects model: baseline, treatment group, visit and treatment group by visit interaction as fixed effects; participant as a random effect
  • Ritlecitinib 200/50 mg QD vs Placebo · Mixed Models Analysis · Least squares mean difference: 0.003 · 95% CI -0.049 to 0.056Linear mixed-effects model: baseline, treatment group, visit and treatment group by visit interaction as fixed effects; participant as a random effect
SecondaryChange From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 9E and 15E

High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.

Time frame:
Baseline, Month 9E and 15E (Month 9 and 15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.
Reported as:
Mean · μV
Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 9E and 15E
μVRitlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QD
Month 9E-0.058 ± 0.1209-0.025 ± 0.1307
Month 15E-0.047 ± 0.1314-0.023 ± 0.1217
SecondaryNumber of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Right Side up to Month 9

Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized descriptively using number of participants by treatment group at each intensity level. At Month 9, 1 participant in 200/50 mg had absence of Wave V on BAEP at a stimulus intensity of 40 dB on the right side. The event was unilateral and showed fluctuations in the presence or absence of Wave V at various intensities on repeat assessments starting at Month 6.

Time frame:
Baseline, Month 6 and 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase)
Reported as:
Count of participants · Participants
Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Right Side up to Month 9
ParticipantsRitlecitinib 200/50 mg QDPlacebo
Baseline - 80 dB of normal hearing level (nHL)00
Baseline - 70 dB nHL00
Baseline - 60 dB nHL00
Baseline - 50 dB nHL00
Baseline - 40 dB nHL00
Month 6 - 80 dB nHL00
Month 6 - 70 dB nHL00
Month 6 - 60 dB nHL00
Month 6 - 50 dB nHL00
Month 6 - 40 dB nHL00
Month 9 - 80 dB nHL00
Month 9 - 70 dB nHL00
Month 9 - 60 dB nHL00
Month 9 - 50 dB nHL00
Month 9 - 40 dB nHL10
SecondaryNumber of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Right Side at Baseline, Month 3E, 6E, 9E and 15E

Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized using number of participants by treatment group at each intensity level. All participants had Wave V on BAEP present at stimulus intensities ranging from 80 dB to 40 dB up to Month 15E except for 1 participant. At Month 9 (TP1), 1 participant in 200/50/50 mg had absence of Wave V on BAEP at a stimulus intensity of 40 dB on the right side. Fluctuations were seen in the presence or absence of Wave V at various intensities on repeat assessments starting at Month 6 on the right side.

Time frame:
Baseline, Month 3E, 6E, 9E and 15E (Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase)
Reported as:
Count of participants · Participants
Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Right Side at Baseline, Month 3E, 6E, 9E and 15E
ParticipantsRitlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QD
Baseline - 80 dB nHL00
Baseline - 70 dB nHL00
Baseline - 60 dB nHL00
Baseline - 50 dB nHL00
Baseline - 40 dB nHL00
Month 3E - 80 dB nHL00
Month 3E - 70 dB nHL00
Month 3E - 60 dB nHL00
Month 3E - 50 dB nHL00
Month 3E - 40 dB nHL00
Month 6E - 80 dB nHL00
Month 6E - 70 dB nHL00
Month 6E - 60 dB nHL00
Month 6E - 50 dB nHL00
Month 6E - 40 dB nHL00
Month 9E - 80 dB nHL00
Month 9E - 70 dB nHL00
Month 9E - 60 dB nHL00
Month 9E - 50 dB nHL10
Month 9E - 40 dB nHL10
Month 15E - 80 dB nHL00
Month 15E - 70 dB nHL00
Month 15E - 60 dB nHL00
Month 15E - 50 dB nHL00
Month 15E - 40 dB nHL00
SecondaryNumber of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Left Side up to Month 9

Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized descriptively using number of participants by treatment group at each intensity level.

Time frame:
Baseline, Month 6 and 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase)
Reported as:
Count of participants · Participants
Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Left Side up to Month 9
ParticipantsRitlecitinib 200/50 mg QDPlacebo
Baseline - 80 dB nHL00
Baseline - 70 dB nHL00
Baseline - 60 dB nHL00
Baseline - 50 dB nHL00
Baseline - 40 dB nHL00
Month 6 - 80 dB nHL00
Month 6 - 70 dB nHL00
Month 6 - 60 dB nHL00
Month 6 - 50 dB nHL00
Month 6 - 40 dB nHL00
Month 9 - 80 dB nHL00
Month 9 - 70 dB nHL00
Month 9 - 60 dB nHL00
Month 9 - 50 dB nHL00
Month 9 - 40 dB nHL00
SecondaryNumber of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Left Side at Baseline, Month 3E, 6E, 9E and 15E

Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized descriptively using number of participants by treatment group at each intensity level. All participants had Wave V on BAEP present at stimulus intensities ranging from 80 dB to 40 dB up to Month 15E except for 1 participant. At Month 9 (TP1), 1 participant in 200/50/50 mg had absence of Wave V on BAEP at a stimulus intensity of 40 dB on the right side. Fluctuations were seen in the presence or absence of Wave V at various intensities on repeat assessments starting at Month 6 on the right side.

Time frame:
Baseline, Month 3E, 6E, 9E and 15E (Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase)
Reported as:
Count of participants · Participants
Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Left Side at Baseline, Month 3E, 6E, 9E and 15E
ParticipantsRitlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QD
Baseline - 80 dB nHL00
Baseline - 70 dB nHL00
Baseline - 60 dB nHL00
Baseline - 50 dB nHL00
Baseline - 40 dB nHL00
Month 3E - 80 dB nHL00
Month 3E - 70 dB nHL00
Month 3E - 60 dB nHL00
Month 3E - 50 dB nHL00
Month 3E - 40 dB nHL00
Month 6E - 80 dB nHL00
Month 6E - 70 dB nHL00
Month 6E - 60 dB nHL00
Month 6E - 50 dB nHL00
Month 6E - 40 dB nHL00
Month 9E - 80 dB nHL00
Month 9E - 70 dB nHL00
Month 9E - 60 dB nHL00
Month 9E - 50 dB nHL00
Month 9E - 40 dB nHL00
Month 15E - 80 dB nHL00
Month 15E - 70 dB nHL00
Month 15E - 60 dB nHL00
Month 15E - 50 dB nHL00
Month 15E - 40 dB nHL00
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Seriousness of an AE was assessed under the criteria of serious adverse event (SAE). An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect, etc. Treatment-emergent events were with onset date occurring during the on-treatment period. Relatedness to study treatment was determined by the investigator.

Time frame:
Approximately 16 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsRitlecitinib 200/50 mg QD - Placebo-Controlled PhasePlacebo - Placebo-Controlled PhaseRitlecitinib 50 mg QD - Active Therapy Extension PhaseRitlecitinib 200/50 mg QD - Active Therapy Extension Phase
TEAE (All-Causality)292233
TEAE (Treatment-Related)9501
TESAE (All-Causality)0110
TESAE (Treatment-Related)0000
SecondaryNumber of Participants Who Discontinued From Study Due to Adverse Event (AEs)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study. Relatedness to study treatment was determined by the investigator.

Time frame:
Approximately 16 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued From Study Due to Adverse Event (AEs)
ParticipantsRitlecitinib 200/50 mg QD - Placebo-Controlled PhasePlacebo - Placebo-Controlled PhaseRitlecitinib 50 mg QD - Active Therapy Extension PhaseRitlecitinib 200/50 mg QD - Active Therapy Extension Phase
Due to All-Causality AEs0010
Due to Treatment-Related AEs0000
SecondaryNumber of Participants Who Discontinued Study Drug Due to AE and Continued Study

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. This Outcome Measures presented the number of participants who had an AE record that indicated that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study. Relatedness to study treatment was determined by the investigator.

Time frame:
Approximately 16 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Drug Due to AE and Continued Study
ParticipantsRitlecitinib 200/50 mg QD - Placebo-Controlled PhasePlacebo - Placebo-Controlled PhaseRitlecitinib 50 mg QD - Active Therapy Extension PhaseRitlecitinib 200/50 mg QD - Active Therapy Extension Phase
Due to All-Causality AEs1000
Due to Treatment-Related AEs0000
SecondaryNumber of Participants With Temporary Drug Discontinuation Due to AEs

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with temporary drug discontinuation due to both all-causality and treatment-related AEs are presented below. Relatedness to study treatment was determined by the investigator.

Time frame:
Approximately 16 months
Reported as:
Count of participants · Participants
Number of Participants With Temporary Drug Discontinuation Due to AEs
ParticipantsRitlecitinib 200/50 mg QD - Placebo-Controlled PhasePlacebo - Placebo-Controlled PhaseRitlecitinib 50 mg QD - Active Therapy Extension PhaseRitlecitinib 200/50 mg QD - Active Therapy Extension Phase
Due to All-Causality AEs6100
Due to Treatment-Related AEs3000
SecondaryNumber of Participants With Clinically Significant Abnormalities in Vital Signs

Oral, tympanic, or axillary temperature, pulse rate, respiratory rate, and blood pressure (BP) were assessed. BP and pulse measurements were assessed in a chair, back supported and arms bared (free of restrictions such as rolled-up sleeves, etc) and supported at heart level. Measurements were taken on the same arm at each visit (preferably non-dominant) with a completely automated device. Pulse rate was measured at approximately the same time as BP for a minimum of 30 seconds. BP and pulse measurements should be preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (eg, television, cell phones). Participants refrained from smoking or ingesting caffeine during the 30 minutes preceding the measurements. The clinical significance was determined by the investigator.

Time frame:
Approximately 16 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Vital Signs
ParticipantsRitlecitinib 200/50 mg QD - Placebo-Controlled PhasePlacebo - Placebo-Controlled PhaseRitlecitinib 50 mg QD - Active Therapy Extension PhaseRitlecitinib 200/50 mg QD - Active Therapy Extension Phase
Number of Participants With Clinically Significant Abnormalities in Vital Signs0000
SecondaryNumber of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values

Safety laboratory assessments included the categories of Hematology, Chemistry, Urinalysis and other tests. The clinical significance was determined by the investigator.

Time frame:
Approximately 16 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values
ParticipantsRitlecitinib 200/50 mg QD - Placebo-Controlled PhasePlacebo - Placebo-Controlled PhaseRitlecitinib 50 mg QD - Active Therapy Extension PhaseRitlecitinib 200/50 mg QD - Active Therapy Extension Phase
Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values0000
SecondaryChange From Baseline in Overall Severity of Alopecia Tool (SALT) Scores up to Month 9

SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. The overall SALT score included hair loss regardless of etiology (ie, scalp hair loss due to both non-AA and AA) and was collected at study visits. The Overall SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.

Time frame:
Baseline, Months 3, 6 and 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Overall Severity of Alopecia Tool (SALT) Scores up to Month 9
Units on a scaleRitlecitinib 200/50 mg QDPlacebo
Month 3-23.0 (-29.70 to -16.25)-2.7 (-9.39 to 4.06)
Month 6-35.2 (-44.55 to -25.81)-5.1 (-14.44 to 4.18)
Month 9-38.2 (-47.46 to -28.86)-6.8 (-16.08 to 2.40)
SecondaryChange From Baseline in Overall SALT Scores at Month 3E, 6E, 9E, 12E and 15E

SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. The overall SALT score included hair loss regardless of etiology (ie, scalp hair loss due to both non-AA and AA) and was collected at study visits. The Overall SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.

Time frame:
Baseline, Month 3E, 6E, 9E, 12E and 15E (Month 3, 6, 9, 12 and 15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase.
Reported as:
Mean · Units on a scale
Change From Baseline in Overall SALT Scores at Month 3E, 6E, 9E, 12E and 15E
Units on a scaleRitlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QD
Baseline69.7 ± 31.5669.6 ± 29.59
Change at Month 3E-41.7 ± 33.98-38.7 ± 33.49
Change at Month 6E-38.0 ± 29.88-43.4 ± 34.13
Change at Month 9E-38.7 ± 29.90-46.6 ± 34.14
Change at Month 12E-41.6 ± 29.67-48.9 ± 34.77
Change at Month 15E-44.6 ± 28.51-49.9 ± 34.40
SecondaryChange From Baseline in Alopecia Areata - Severity of Alopecia Tool (AA-SALT) Score up to Month 9

SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. AA-SALT is the amount of scalp hair loss due to AA. AA SALT score in Placebo-Controlled Phase = overall SALT score - non-AA SALT score (The non-AA SALT score only took into account scalp hair loss other than that due to AA and was required to be assessed only at Month 9 \[or Month 6 for those who entered the Active Therapy Extension Phase at Month 6\] in Placebo-Controlled Phase). The AA-SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.

Time frame:
Baseline, Months 3, 6 and 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Alopecia Areata - Severity of Alopecia Tool (AA-SALT) Score up to Month 9
Units on a scaleRitlecitinib 200/50 mg QDPlacebo
Month 3-23.0 (-29.70 to -16.25)-2.7 (-9.39 to 4.06)
Month 6-35.2 (-44.55 to -25.81)-5.1 (-14.44 to 4.18)
Month 9-38.2 (-47.46 to -28.87)-6.8 (-16.08 to 2.40)
SecondaryChange From Baseline in AA-SALT Score at Month 3E, 6E, 9E, 12E and 15E

SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. AA-SALT is the amount of scalp hair loss due to AA. AA SALT score = overall SALT score - non-AA SALT score (The non-AA SALT score only took into account scalp hair loss other than that due to AA and was required to be assessed only at Month 9 \[or Month 6 for those who entered the Active Therapy Extension Phase at Month 6\] in Placebo-Controlled Phase). The AA-SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.

Time frame:
Baseline, Month 3E, 6E, 9E, 12E and 15E (Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase)
Reported as:
Mean · Units on a scale
Change From Baseline in AA-SALT Score at Month 3E, 6E, 9E, 12E and 15E
Units on a scaleRitlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QD
Baseline67.0 ± 33.5269.5 ± 29.67
Change at Month 3E-41.7 ± 33.97-39.4 ± 32.89
Change at Month 6E-38.0 ± 29.87-44.2 ± 33.37
Change at Month 9E-38.7 ± 29.90-47.4 ± 33.36
Change at Month 12E-41.6 ± 29.70-49.7 ± 33.92
Change at Month 15E-44.8 ± 28.37-50.8 ± 33.49
SecondaryNumber of Participants With Patient's Global Impression of Change (PGI-C) Response up to Month 9

The PGI-C asked the participants to evaluate the improvement or worsening of their AA as compared to the start of the study using a single item, "Since the start of the study, my alopecia areata has: …". The participants selected one of seven responses ranging from "greatly improved" to "greatly worsened". This Outcome Measure presented the number of participants with PGI-C response which was defined as "greatly improved" or "moderately improved". Participants with missing PGI-C scores were considered as non-responders.

Time frame:
Months 1, 3, 6 and 9
Reported as:
Count of participants · Participants
Number of Participants With Patient's Global Impression of Change (PGI-C) Response up to Month 9
ParticipantsRitlecitinib 200/50 mg QDPlacebo
Month 143
Month 3206
Month 62110
Month 9196
SecondaryNumber of Participants With PGI-C Response at 3E, 6E, 9E, 12E and 15E

The PGI-C asked the participants to evaluate the improvement or worsening of their AA as compared to the start of the study using a single item, "Since the start of the study, my alopecia areata has: …". The participants selected one of seven responses ranging from "greatly improved" to "greatly worsened". This Outcome Measure presented the number of participants with PGI-C response which was defined as "greatly improved" or "moderately improved". Participants with missing PGI-C scores were considered as non-responders.

Time frame:
Month 3E, 6E, 9E, 12E and 15E
Reported as:
Count of participants · Participants
Number of Participants With PGI-C Response at 3E, 6E, 9E, 12E and 15E
ParticipantsRitlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QD
Month 3E2222
Month 6E1620
Month 9E2018
Month 12E1718
Month 15E1718
SecondaryNumber of Participants With TEAEs and TESAEs: Extension Phase (TP3)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Seriousness of an AE was assessed under the criteria of SAE. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect, etc. Treatment-emergent events were with onset date occurring during the on-treatment period. Relatedness to study treatment was determined by the investigator.

Time frame:
From first dose of treatment up to 28 days follow up after last dose of study treatment (Approximately 19 months)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs and TESAEs: Extension Phase (TP3)
ParticipantsRitlecitinib 50 mg QD
TEAEs19
TESAEs1
SecondaryNumber of Participants Who Discontinued From Study Due to AEs: Extension Phase (TP3)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study. Relatedness to study treatment was determined by the investigator.

Time frame:
From first dose of treatment up to 28 days follow up after last dose of study treatment (Approximately 19 months)
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued From Study Due to AEs: Extension Phase (TP3)
ParticipantsRitlecitinib 50 mg QD
Number of Participants Who Discontinued From Study Due to AEs: Extension Phase (TP3)1
SecondaryNumber of Participants Who Discontinued Study Drug Due to AE and Continued Study: Extension Phase (TP3)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. This outcome measure presented the number of participants who had an AE record that indicated that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study. Relatedness to study treatment was determined by the investigator.

Time frame:
From first dose of treatment up to 28 days follow up after last dose of study treatment (Approximately 19 months)
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Drug Due to AE and Continued Study: Extension Phase (TP3)
ParticipantsRitlecitinib 50 mg QD
Number of Participants Who Discontinued Study Drug Due to AE and Continued Study: Extension Phase (TP3)0
SecondaryNumber of Participants With Temporary Drug Discontinuation Due to AEs: Extension Phase (TP3)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with temporary drug discontinuation due to both all-causality and treatment-related AEs are presented below. Relatedness to study treatment was determined by the investigator.

Time frame:
From first dose of treatment up to 28 days follow up after last dose of study treatment (Approximately 19 months)
Reported as:
Count of participants · Participants
Number of Participants With Temporary Drug Discontinuation Due to AEs: Extension Phase (TP3)
ParticipantsRitlecitinib 50 mg QD
Number of Participants With Temporary Drug Discontinuation Due to AEs: Extension Phase (TP3)1
SecondaryNumber of Participants With Clinically Significant Abnormalities in Vital Signs: Extension Phase (TP3)

Oral, tympanic, or axillary temperature, pulse rate, respiratory rate, and blood pressure (BP) were assessed. BP and pulse measurements were assessed in a chair, back supported and arms bared (free of restrictions such as rolled-up sleeves, etc) and supported at heart level. Measurements were taken on the same arm at each visit (preferably non-dominant) with a completely automated device. Pulse rate was measured at approximately the same time as BP for a minimum of 30 seconds. BP and pulse measurements preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (eg, television, cell phones). Participants were refrained from smoking or ingesting caffeine during the 30 minutes preceding the measurements. The clinical significance was determined by the investigator.

Time frame:
From screening up to 28 days follow up after last dose of study treatment (maximum up to 19 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Vital Signs: Extension Phase (TP3)
ParticipantsRitlecitinib 50 mg QD
Number of Participants With Clinically Significant Abnormalities in Vital Signs: Extension Phase (TP3)0
SecondaryNumber of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values: Extension Phase (TP3)

Safety laboratory assessments included the categories of hematology, chemistry, urinalysis and other tests. The clinical significance was determined by the investigator.

Time frame:
From screening up to 28 days after last dose of study treatment (maximum up to 19 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values: Extension Phase (TP3)
ParticipantsRitlecitinib 50 mg QD
Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values: Extension Phase (TP3)0

Adverse events

Collected over Placebo controlled phase (TP1) & Active therapy extension phase (TP2): 24 months, Extension phase (TP3): From first dose of treatment up to 28 days follow up after last dose of study treatment (Approximately 19 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ritlecitinib 200/50 mg QD - Placebo-Controlled Phase0/36 (0%)0/36 (0%)23/36 (63.9%)
Placebo - Placebo-Controlled Phase0/35 (0%)1/35 (2.9%)17/35 (48.6%)
Ritlecitinib 50 mg QD - Active Therapy Extension Phase0/32 (0%)2/32 (6.3%)16/32 (50%)
Ritlecitinib 200/50 mg QD - Active Therapy Extension Phase0/33 (0%)1/33 (3%)12/33 (36.4%)
Ritlecitinib 50 mg QD: Extension Phase0/45 (0%)1/45 (2.2%)10/45 (22.2%)
Most frequent serious events
Most frequent serious events
EventRitlecitinib 200/50 mg QD - Placebo-Controlled PhasePlacebo - Placebo-Controlled PhaseRitlecitinib 50 mg QD - Active Therapy Extension PhaseRitlecitinib 200/50 mg QD - Active Therapy Extension PhaseRitlecitinib 50 mg QD: Extension Phase
Takayasu's arteritisVascular disorders0/360/351/320/330/45
Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/360/351/320/330/45
Chronic pigmented purpuraSkin and subcutaneous tissue disorders0/360/350/321/330/45
Humerus fractureInjury, poisoning and procedural complications0/361/350/320/330/45
Biliary colicHepatobiliary disorders0/360/350/320/331/45
Most frequent other events
Showing 10 of 27
Most frequent other events
EventRitlecitinib 200/50 mg QD - Placebo-Controlled PhasePlacebo - Placebo-Controlled PhaseRitlecitinib 50 mg QD - Active Therapy Extension PhaseRitlecitinib 200/50 mg QD - Active Therapy Extension PhaseRitlecitinib 50 mg QD: Extension Phase
COVID-19Infections and infestations3/363/355/326/331/45
Acne pustularInfections and infestations4/360/350/320/330/45
HeadacheNervous system disorders4/361/350/323/330/45
NasopharyngitisInfections and infestations2/361/353/322/332/45
ParaesthesiaNervous system disorders1/361/353/320/330/45
NauseaGastrointestinal disorders1/363/350/320/330/45
HypoaesthesiaNervous system disorders1/363/352/320/330/45
DiarrhoeaGastrointestinal disorders3/360/350/320/331/45
VomitingGastrointestinal disorders3/361/351/320/330/45
DizzinessNervous system disorders3/361/350/320/330/45

Baseline characteristics

Baseline analysis population included all participants taking at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)Ritlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QDTotal
Mean35.1 ± 9.6434.2 ± 8.9534.7 ± 9.25
Sex: Female, Male
Sex: Female, Male(Participants)Ritlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QDTotal
Female252550
Male111021
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ritlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QDTotal
American Indian or Alaska Native000
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American7411
White262854
More than one race022
Unknown or Not Reported011
Baseline Percentage of Nerve Fibers With Axonal Swelling
Baseline Percentage of Nerve Fibers With Axonal Swelling(Percentage of Nerve Fibers)Ritlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QDTotal
Mean1.8 ± 2.481.8 ± 2.071.8 ± 2.27
Baseline Intraepidermal Nerve Fiber Density (IENFD)
Baseline Intraepidermal Nerve Fiber Density (IENFD)(fibers/mm)Ritlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QDTotal
Mean10.2 ± 3.8111.0 ± 3.9510.6 ± 3.87
Baseline Severity of Alopecia Tool (SALT) Scores for Non-AT/AU Participants
Baseline Severity of Alopecia Tool (SALT) Scores for Non-AT/AU Participants(Units on a scale)Ritlecitinib 200/50/50 mg QDPlacebo -> Ritlecitinib 200/50 mg QDTotal
Mean59.6 ± 30.3153.7 ± 24.1856.9 ± 27.55
08

Study locations

38 sites
  • Marvel Clinical Research 002, LLC
    Huntington Beach, California 92647, United States
  • University of California, Irvine
    Irvine, California 92697, United States
  • Skin Care Research, LLC
    Boca Raton, Florida 33486, United States
  • Skin Care Research, LLC
    Hollywood, Florida 33021, United States
  • Kendall Adkisson, MD - Intracoastal Dermatology
    Jacksonville, Florida 32224, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Y&L Advance Health Care Inc., d/b/a Elite Clinical Research
    Miami, Florida 33144, United States
  • BRCR Medical Center Inc
    Miramar, Florida 33027, United States
  • Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
    Orlando, Florida 32801, United States
  • Orlando Dermatology & Skin Cancer Surgery Center
    Oviedo, Florida 32765, United States
  • USF Health Morsani Center For Advanced Healthcare
    Tampa, Florida 33612, United States
  • NorthShore University HealthSystem Dermatology Clinical Trials Unit
    Skokie, Illinois 60077, United States
  • NorthShore University HealthSystem Dermatology Clinic
    Skokie, Illinois 60077, United States
  • Washington University School of Medicine-Dermatology
    St Louis, Missouri 63108, United States
  • University of New Mexico Department of Dermatology
    Albuquerque, New Mexico 87102, United States
  • University of New Mexico Clinical & Translational Sciences Center
    Albuquerque, New Mexico 87106, United States
  • Stony Brook Dermatology
    Stony Brook, New York 11790, United States
  • M3 Wake Research, Inc.
    Raleigh, North Carolina 27612, United States
  • Tekton Research, Inc.
    Austin, Texas 78745, United States
  • Center for Clinical Studies, LTD. LLP
    Houston, Texas 77004, United States
  • Summit Clinical Research, LLC
    Franklin, Virginia 23851, United States
  • The Education & Research Foundation, Inc.
    Lynchburg, Virginia 24501, United States
  • Virginia Dermatology and Skin Cancer Center
    Norfolk, Virginia 23502, United States
  • Premier Specialists Pty Ltd
    Kogarah, New South Wales 2217, Australia
  • Eastern Health - Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X2, Canada
  • SKiN Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • Sima Recherche
    Verdun, Quebec H4G 3E7, Canada
  • Centre de Recherche Saint-Louis
    Québec, G1W4R4, Canada
  • Niepubliczny Zaklad Opieki Zdrowotnej Specjalistyczny Osrodek Dermatologiczny "DERMAL"
    Bialystok, 15-453, Poland
  • Centrum Medyczne Angelius Provita
    Katowice, 40-611, Poland
  • AWP Klinika Dermatologii Pod Fortem Anna Wojas-Pelc
    Krakow, 31-302, Poland
  • Dermedic Jacek Zdybski
    Ostrowiec Świętokrzyski, 27-400, Poland
  • RCMed Oddzial Warszawa
    Warsaw, 00-892, Poland
  • MTZ Clinical Research Powered by Pratia
    Warsaw, 02-172, Poland
  • Przychodnia przy ul. Lowieckiej
    Wroclaw, 50-220, Poland
  • Centrum Medyczne Matusiak
    Wroclaw, 50-566, Poland
09

References and documents

Publications

  • Senna M, Soung J, Figueras I, King B, Kinoshita-Ise M, Hanna S, Wu W, Wajsbrot D, Woodworth D, Wolk R, Chaudhry A, Lejeune A, Tran H. Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies. Am J Clin Dermatol. 2026 Mar 31. doi: 10.1007/s40257-026-01029-y. Online ahead of print. PubMed 41917311 ↗
  • King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Mesinkovska NA, Paul C, Gong Y, Anway SD, Tran H, Wolk R, Zwillich SH, Lejeune A. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. Am J Clin Dermatol. 2024 Mar;25(2):299-314. doi: 10.1007/s40257-024-00846-3. Epub 2024 Jan 23. PubMed 38263353 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Jan 2022, 15 months.

Results were first posted in Dec 2022, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2020
First posted
Aug 18, 2020
StartActual
Sep 15, 2020
Primary completionActual
Jan 4, 2022
CompletionActual
May 7, 2024
Results first posted
Dec 28, 2022
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04517864
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 18, 2020
Start date
Sep 15, 2020
Primary completion
Jan 4, 2022
Completion
May 7, 2024
Results posted
Dec 28, 2022
Last update
Jul 11, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion